Brammer Bio, a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for gene and cell therapies, will be part of Thermo Fisher’s pharma services business within its laboratory products and services segment following the $1.7bn (€1.5bn) agreement.
The transaction is expected to be completed by the end of the second quarter of 2019.
Brammer Bio’s viral vector capabilities will meet Thermo Fisher’s good manufacturing practice (GMP) production experience and bioprocessing and cell culture technologies to enable the company to partner with customers in the gene therapy market.
Brammer Bio is expected to deliver $250m of revenue in 2019 and continue to grow at a rate of 25% over the mid-term. The CDMO employs approximately 600 at offices in Cambrige, MA and Alachua, FL.
Marc Casper, president and CEO of Thermo Fisher Scientific said in a statement, “Gene therapy is an area of increasing focus for our customers and is fast-evolving given its potential to treat a range of genetic disorders.”
The Brammer Bio deal marks the second CDMO purchase for Thermo Fisher following its 2017 acquisition of Patheon.
The $7.2bn agreement augmented Thermo Fisher’s bioproduction and biologics development and manufacturing capabilities.
Thermo Fisher did not respond to a request for comment.